Hargreaves Lansdown investors are buying GSK shares. Should I?

GlaxoSmithKline plc (LON:GSK) shares were hot last week as investors piled in. Paul Summers considers whether he’d buy now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

FTSE 100 giant GlaxoSmithKline (LSE: GSK) was the most popular buy on investment platform Hargreaves Lansdown last week. Today, I’m asking whether I should be joining other investors in adding GSK shares to my own portfolio.

GSK shares: FTSE 100 laggard

Based purely on the performance of its share price over the last five years, it’s tempting to give GlaxoSmithKline a ‘hard pass’. GSK’s value is now 10% lower than it was in April 2016. It’s also been one of the worst shares to own in the FTSE 100 over the last year.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Considering the recovery seen in markets since the 2020 crash — not to mention Glaxo’s status as the biggest producer of vaccines in the world — this is quite some ‘achievement’. Then again, the fact that the company hasn’t come up with a Covid-19 vaccine so far hasn’t gone down well. It also helps to explain why shares in peer Astrazeneca have soared. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

On top of this, there’s a distinct possibility that GSK will be forced to reduce its dividend payouts going forward to free up cash to invest in its drug development pipeline. This makes complete sense, but it’s not what those who own the shares for their dependable income want to hear. In fact, it underlines the point that no investment is ever devoid of risk.

So, why are Hargreaves Lansdown investors suddenly interested?

Activists assemble

It all seems to be down to recent news that activist investor Elliott Management has declared a multi-billion pound stake in GSK. Activist investors tend to get the market excited because they can be a catalyst for change at a flagging company.

US-based hedge fund Elliott certainly has form when it comes to ruffling feathers. It previously pushed for change at Premier Inn owner Whitbread and had a few bruising encounters with FTSE 100 miner BHP Group.

Of course, whether its involvement leads to a seismic change of strategy remains to be seen. It certainly comes at an interesting time given GSK’s plan to list its consumer healthcare business as a separate entity next year. There’s always a chance that its involvement could make things worse.

Regardless, I think there are reasons to be positive about GSK shares. 

Defensive play

For one, demand for Glaxo’s products, such as the highly successful shingles jab Shingrix, should recover once the pandemic has passed. A host of new launches are also expected over the next five years.

In addition, there’s a lot to be said for buying highly defensive shares now. With markets around the world looking frothy once again, any wobbles will likely be felt most in hyped growth plays, not stock-for-all-seasons Glaxo. Even if markets were to continue rising, it’s quite possible that companies offering value will be the ones to thrive.

Moreover, I think those dividends are worth grabbing. A likely 80p per share return for 2021 gives a yield of 6%. If the payout is reduced by 20% in 2022 (the consensus forecast), the subsequent 4.8% yield is still very decent.

And then there’s the price. At 13 times forecast FY21 earnings, I think Glaxo offers great value.

Bottom line

GSK shares have been in the doldrums for a long time and perhaps justifiably so. It remains a contrarian bet for now.

Notwithstanding this, I’d be comfortable buying GSK shares at today’s price. As with investing in general, patience is key.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Hargreaves Lansdown. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

3 shares to consider for long-term passive income

Christopher Ruane thinks investors on the hunt for passive income streams should consider this diverse trio of dividend-paying shares.

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Here are the latest dividend yield forecasts for Legal & General, Aviva, and M&G shares

If someone’s looking for high dividend yields on the London Stock Exchange, these three Footsie financial stocks are definitely worth…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Growth Shares

Up 68% but still yielding 7.1%, I’ve been loading up on Aberdeen shares

The FTSE 250 is loaded full of great businesses with significant growth potential. This writer believes Aberdeen shares to be…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Is the Vodafone resurgence on, as results and a buyback boost the share price?

The Vodafone share price has been ticking up in 2025. Is that a sign the company's bold restructuring plans are…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

The Legal & General share price is rising. Will it soon be too late to bag big dividends?

The Legal & General share price has had an unremarkable decade, but it currently has one of the Footsie's biggest…

Read more »

Mother At Home Getting Son Wearing Uniform Ready For First Day Of School
Investing Articles

Open a SIPP for your baby and maybe they can retire early

The SIPP's an incredibly valuable vehicle for our investments and it can be leveraged to provide us with an early…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Are dividend shares a good way of getting rich? Here’s what Warren Buffett thinks

Dividend shares can be great passive income investments, but when it comes to building wealth, Warren Buffett is clear on…

Read more »

Young woman holding up three fingers
Investing Articles

3 excellent ETFs to consider for a Stocks and Shares ISA

These three mega-trends look set to make investors a lot wealthier in future. Here are three thematic ETFs that I…

Read more »